Diabetes

Increase productivity, strengthen camaraderie among colleagues, and motivate an even sharper focus on serving our patients. Sounds like a win-win-win, and it is! Here is how to do it.

The FDA has approved the longest-lasting self-applied continuous glucose monitor (CGM) in the United States market.

The FDA has approved the FreeStyle Libre 14-day Flash Glucose Monitoring system, now the longest-lasting self-applied continuous glucose monitor (CGM) in the US market.

A look at last week's top stories in the world of pharmacy.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

When it comes to diabetes, that lack of a shared language can be a tremendous barrier to care.

Study establishes increased risk of all-site cancer for both men and women with diabetes, but the excess risk of cancer is greater for women.

Growing evidence suggests that integrating clinical pharmacy specialists into medical care teams that focus on diabetes improves glycemic control, and leads to better clinical outcomes in primary care settings.

Study: Vitamin E was related to significant reductions in blood glucose and glycated hemoglobin compared with the placebo.

Patients on atypical antipsychotics have 3 to 5 times greater risk of type 2 diabetes than others.

Rachele Berria, MD, PhD, Vice President and Head of the Diabetes Medical Unit at Sanofi, explains the role of pharmacists in helping patients manage their diabetes.

Ronnie Aronson, MD, FRCPC, FACE, Medical Director of LMC Diabetes and Endocrinology, discusses the key role pharmacists play in treating patients with CGM systems.

New data demonstrate that evolocumab (Repatha) significantly reduced low-density lipoprotein cholesterol and non-high density lipoprotein cholesterol in patients with type 2 diabetes plus hypercholesterolemia or mixed dyslipidemia.

Newly published findings from the PIONEER 1 phase 3a trial show that once-daily once-daily oral semaglutide was associated with significant reductions in blood sugar in adults with type 2 diabetes.

In addition to showing no significant imbalance of BKLE amputation, the study also identified a HHF reduction in the general T2D population.

People with T2D have an increased risk of damage to the eyes, kidneys, nerves, legs, heart and brain, and many of these complications can ultimately affect mortality.

Risk factor modification remains key to managing patients with HIV and diabetes.

In this video, Priscilla Hsue, MD, from the University of California San Francisco School of Medicine, explains other health issues patietns with HIV may face as they age.

Kathryn Kreider, DNP, FNP-BC, BC-ADM, explains diabetes associations and the implications it has on health management for patients with diabetes.